Background Since 2014, England has seen increased scarlet fever activity unprecedented in modern times. In 2016, England's scarlet fever seasonal rise coincided with an unexpected elevation in invasive Streptococcus pyogenes infections. We describe the molecular epidemiological investigation of these events.
Introduction
Scarlet fever is a classic exanthem of childhood caused by the bacterium Streptococcus pyogenes (group A strepto coccus) that, until the beginning of the 20th century, was associated with frequent loss of life among children. 1 By the start of the 20th century, long before widespread use of antibiotics, the incidence and severity of scarlet fever had begun to fall, a phenomenon that remains largely unexplained. 2 One potential (untestable) hypothesis is that the streptococcal bacteria causing the disease might have undergone a pathogenetic change that led to a reduction in the invasive and septic sequelae of scarlet fever.
Since the 1940s, scarlet fever has followed a seasonal springtime pattern-peaking between March and May while remaining less frequent throughout the rest of the year-without the major cyclical epidemics observed in the early 20th century. 3 Surges in invasive infections can periodically follow a similar seasonal pattern for reasons that are incompletely understood. In 2014, England had an unexpected surge in scarlet fever infections, with over 15 000 disease notifications-a marked increase in inci dence compared with previous decades. 3, 4 Despite having a major impact on public health resources, 3 the increase in infections was not associated with any rise in the incidence of invasive disease. Even greater seasonal upsurges of scarlet fever were observed in 2015, when there were over 17 000 notifications, and in 2016, when there were over 19 000 notifications. 3 In the spring of 2016, there was a 1·5times increase in the number of laboratoryconfirmed invasive S pyogenes infections compared with that in the previous 5 years, coinciding with the peak in scarlet fever notifications. 3, 5 The absence of any association between scarlet fever notifications and increased invasive infection notifications in 2014 3 led us to speculate that the association of scarlet fever with invasive disease in 2016 might be strain dependent.
Microbiological surveillance of S pyogenes upper respiratory tract infections in England is constrained, as most doctors do not routinely take samples for bacteriological diagnosis of sore throat. However, all S pyogenes isolates cultured from samples submitted from the population of northwest London are collected and archived by the Imperial College Infection Biobank, allowing longitudinal study of strains causing both non invasive and invasive infections. Alongside the national reference laboratory, which systematically archives invasive S pyogenes isolates from across the country, the collection provides unique insight into the relationship between upper respiratory tract isolates and isolates from rare, but more severe and invasive, infections.
S pyogenes can be serotyped or genotyped on the basis of the M antigen, which is encoded by the emm gene. Changes in disease incidence are sometimes characterised by expan sion of specific emm genotypes. 4 Using a combination of epidemiological and bacteriological approaches, we set out to identify the emm genotypes
Research in context
Evidence before this study In March to May of 2016, an unexpected elevation in notifications of invasive Streptococcus pyogenes infections in England was seen, coinciding with a national increase in notifications of seasonal scarlet fever (a paediatric exanthem also caused by S pyogenes). Since 2014, scarlet fever notifications in England have reached unexpectedly high levels, peaking between March and May each year, although notifications of invasive S pyogenes infections in 2014 were within expected limits, in contrast to 2016. We aimed to test the hypothesis that the link between scarlet fever and invasive infection patterns might be strain-related and, in the process, identified the emergence of a new M1T1 lineage. We searched PubMed for clinical and laboratory studies published before March 1, 2019, using the search terms "scarlet fever" and "upsurge" or "mortality", as well as "emm1" or "M1T1" and "streptococcus". We also searched using the terms "SpeA" or "scarlet fever toxin" or "erythrogenic toxin" and "streptococcus" and "regulation". We identified studies describing recent and historical trends in scarlet fever incidence, studies that described trends in strain types causing invasive infections, and studies that linked SpeA to dominant strains. We also found studies of toxin expression that reported links with phage induction, growth phase regulation, transcriptional regulators, proteolysis, and host proteins as potential regulators.
Added value of this study
Our study provides a molecular explanation for the association between increased incidence of scarlet fever and increased incidence of invasive S pyogenes infections, by identifying an emergent lineage of M1T1 S pyogenes (M1 UK ) that expanded rapidly to become the largest single contributor to both non-invasive and invasive infections in 2016. The findings raise the possibility that historical associations between epidemic waves of scarlet fever and invasive infections might also have been linked to strain pathogenicity, in addition to general population susceptibility. Genomic analysis confirmed that the strains that cause scarlet fever are no different to those that cause streptococcal pharyngitis and rarer invasive infections. Increases in one disease could lead to increases in all, particularly if the lineage involved is highly pathogenic. The emergent lineage was characterised by a number of genetic changes that were predictive of increased production of SpeA, and this increased production was confirmed by laboratory testing. Although this might be just one of many changes in the new lineage, increased production of SpeA is predicted to enhance bacterial fitness, as suggested by the increasing dominance of the new lineage in comparison to older M1T1 strains in England. The work highlights that group A streptococcal lineages can differ in pathogenicity.
Implications of all the available evidence
Scarlet fever notifications in England in the period 2014-18 are the highest seen since 1960, and incidence in young children exceeds that reported in other countries. It is uncertain whether the increase in scarlet fever is a result of practice change or other population or environmental factors; the new lineage described is not implicated in the initial upsurge. However, there is a need to curtail this increasing trend. Interventions targeted at the population at risk have the potential to reduce the reservoir of S pyogenes that can seed more harmful invasive infections. Research to identify the most appropriate intervention is underway and practice guidelines for streptococcal pharyngitis might need to take strain variation and wider population effects into account. Increased S pyogenes disease activity could provide a platform for strain evolution and expansion, highlighting an unforeseen consequence of modern epidemics. The genetic changes in the emergent M1T1 clone require detailed laboratory investigation to understand the wider phenotypic changes that have occurred and the molecular basis for these, including transmissibility and response to treatment. It is not known whether the new lineage will recede in due course, as other lineages have done, or if it will remain dominant in the population, and surveillance is needed. Detection of new lineage representatives outside the UK underlines a need for global surveillance and increased vigilance if strains with increased fitness and altered phenotype are detected. responsible for S pyogenes infections during the 2014-16 scarlet fever seasons regionally, then extended the study nationally, to identify bacterial determinants that might explain the observed increase in invasive disease due to S pyogenes in 2016.
Methods

S pyogenes notifications
Cases of suspected scarlet fever are notified by clinicians to Public Health England on the basis of symptoms and signs consistent with scarlet fever, with or without laboratory confirmation of S pyogenes infection. Scarlet fever has been notifiable since 1899 in England. Since 2010, cases of invasive S pyogenes infections have also been notifiable to Public Health England, in accordance with statutory regulations.
S pyogenes isolates and emm genotyping
All noninvasive S pyogenes isolates submitted to the Diagnostic Laboratory at Imperial College Healthcare National Health Service Trust (London, UK) between Jan 1, 2009 and Dec 31, 2013, and between March 1 and May 31 each year during 2014-16 were cultured and stored frozen in glycerol (sampling rationale is detailed in the appendix p 29). This laboratory serves northwest London, a population of roughly 2 million people, representing approximately 3% of the population of England. Clinical data were linked to isolates and anonymised in accordance with research ethics approval (number 06/Q0406/20). Isolates were emm genotyped (appendix p 29). Laboratories from England and Wales are requested to submit sterile site and invasive S pyogenes isolates to the national reference laboratory, where emm genotyping is done on all submitted isolates. All isolates were cultured on Columbia blood agar (Oxoid, Basingstoke, UK) or in ToddHewitt broth (Oxoid) at 37°C with 5% CO 2 .
Genome sequencing
All noninvasive emm1 S pyogenes isolates collected from northwest London from 2009 to 2016 were subject to genome sequencing (appendix p 29), as were invasive emm1 isolates collected from England and Wales from March to May of 2013 and 2016. Comparative genomic analysis of invasive isolates was done with new (2013 and 2016) and existing (2014-15) 6 genome sequence data (appendix p 12-27). DNA from S pyogenes isolates was prepared, sequenced, analysed, and compared with published data from the UK (2007-12), North America, Nordic regions, and southeast Asia 6-11 (appendix pp 28-29). All new genome sequence data generated in this study have been submitted to the European Nucleotide Archive) under the accession numbers listed in the appendix (pp 8, 12).
Quantification of speA production
Transcript expression of speA, encoding streptococcal pyrogenic exotoxin A (SpeA; also known as scarlet fever or erythrogenic toxin A), was quantified by realtime PCR using a standard curve method. SpeA protein expression in 5 × concentrated overnight supernatants was assessed with western blotting, and compared with a recombinant SpeA standard (appendix pp 29, 30) . For SpeA protein testing, one or two isolates per year (2009-15) per lineage (M1 global vs M1 UK ) were randomly selected by lot, after excluding any strains with mutations in the twocomponent regulator covRS (also known as csrRS), which is known to repress a number of virulence factors, including SpeA. 12
Statistical analysis
Datasets were compared with a twotailed Mann Whitney U test for continuous data or a χ² test for categorical data, using GraphPad Prism 5.0 software. p values less than 0·05 were considered to indicate statistical significance. To assess trends in invasive disease incidence, Poisson regression in Stata (version 15) was done using midyear population denominators for England from the Office for National Statistics.
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
The northwest London population had a yearonyear rise in scarlet fever notifications between 2014 and 2016 that was representative of the country as a whole when compared with national notification data (figure 1A). We also compared notifications of invasive S pyogenes infections in northwest London with national data (appendix p 2), which showed a marked increase in S pyogenes invasive disease in 2016 in northwest London during the scarlet fever season that also mirrored the national pattern of increased notifications in 2016.
emm genotypes of all S pyogenes upper respiratory tract isolates obtained in northwest London during the scarlet fever seasons spanning 2015 and 2016 were ascertained and compared with existing data from 2014. 4 emm1 upper respiratory tract strains increased in frequency yearonyear in the scarlet fever seasons, from five (5%) of 96 isolates in 2014, to 28 (19%) of 147 isolates in 2015 (p=0·0021 vs 2014 value), and 47 (33%) of 144 in 2016 (p=0·0080 vs 2015 value); in 2016, emm1 became the single most frequent S pyogenes genotype causing upper respiratory tract infections (figure 1B). The increase in emm1 strains in 2016 contrasted with the previously reported associations of emm3 and emm4 strains with the initial upsurge in scarlet fever in 2014. 4 Brief clinical details were supplied for 243 of 387 upper respiratory tract isolates overall, among which 53 (22%) mentioned scarlet fever. Of these scarlet feverassociated isolates, those genotyped as emm1 increased from zero (0%) of 17 in 2014, to four (24%) of 17 in 2015, and seven (37%) of 19 in 2016 (p=0·0053 vs 2014 value).
To identify any genetic basis for the expansion of emm1 S pyogenes among upper respiratory tract isolates collected in London, the genomes of all noninvasive emm1 isolates available from northwest London from 2009 to 2016 were sequenced (n=135). Singlenucleotide polymorphism (SNP)based analysis of emm1 strains pointed to the emergence of a new emm1 lineage (designated M1 UK ), which could be differentiated from the contemporary emm1 population (M1 global ) by the presence of 27 core SNPs in regulatory and metabolic genes (figure 2, appendix p 7). The earliest member of the M1 UK lineage was identified in 2010, and five intermediate isolates (with 13 or 23 of the unique SNPs) were detected between 2009 and 2012 (appendix p 3). Similarly to M1 global , M1 UK isolates were identified among all age groups, but included more cases of scarlet fever and evidence of recent transmissions than M1 global (appendix p 3). From 2015 onwards, around twothirds of noninvasive emm1 isolates from northwest London were within the new M1 UK lineage (22 [71%] of 31 isolates in 2015, and 30 [65%] of 46 in 2016). Recombination and pangenome analyses provided no evidence for gain or loss of transferable elements when comparing M1 global and M1 UK strains. Lineagespecific acquisition of antimicrobial resistance genes was not detected; evidence of the mefA and msrD macrolideresistance locus was found in just one M1 UK isolate, while eight M1 global isolates possessed antimicrobialresistance genes (one isolate with the mefA and msrD locus, one with the tetracyclineresistance gene tetM, and six with the aminoglycosideresistance gene aph3).
Scarlet fever is a toxinmediated syndrome, historically associated with the expression of the phageencoded erythrogenic toxin SpeA, 13 the gene for which is possessed by all emm1 isolates studied in this investigation. Among the 27 M1 UK lineagedefining SNPs, three non synonymous mutations were identified in the gene rofA encoding the standalone transcriptional regulator RofA, 14 which, alongside a homologue, nra, has been implicated as a repressor of SpeA production in some, but not all, streptococcal genotypes. 15, 16 Realtime PCR analysis of all sequenced noninvasive emm1 isolates from northwest London (n=135) indicated that the emergent lineage (M1 UK ) was associated with significantly increased transcription of speA compared with other contemporary emm1 isolates (M1 global ), suggesting that differential SpeA production was a feature of the M1 UK lineage ( figure 3A) .
To ascertain whether this difference in transcription translated into a difference in SpeA protein expression, we compared ten M1 UK (including one intermediate strain harbouring only 13 of the 27 lineagedefining SNPs) and ten M1 global isolates and corroborated our finding that M1 UK isolates had enhanced speA transcription ( figure 3B ). Quantitative western blot analysis of SpeA protein in bacterial overnight culture supernatant showed ninetimes greater median SpeA production in the emergent M1 UK lineage (190·2 ng/mL [IQR 168·9-200·4]) than in the M1 global strains (20·9 ng/mL [0·0-27·3]; p<0·0001; figure 3C ). The M1 UK strain representing an intermediate genotype (13 of 27 SNPs, including the rofA SNPs) did not show enhanced SpeA protein secretion ( figure 3C) .
The sequence for speA in noninvasive M1 UK and M1 global isolates was identical to that of the reference strain MGAS5005. Integration sites for the phage carrying speA in sequenced noninvasive M1 UK and M1 global isolates were consistent with those in the reference strain, and mapped sequences from M1 UK and M1 global isolates were very similar (if not identical) to the reference strain phage 5005.1; no evidence of translocated superantigens or duplication of speA was found.
Although there was no rise in invasive disease notifications in 2014, the first year of elevated scarlet fever activity, a marked increase was seen nationally in the spring of 2016 compared with the same period (March to May) in the preceding 3 years (rate ratio 1·43 [95% CI 1·31-1·56], p<0·001; appendix p 2). Although invasive disease case numbers in northwest London were modest when considered on a monthly basis by comparison with national data (appendix p 2), the seasonal increase in notifications matched that observed nationally. emm genotyping of all invasive disease isolates referred to the national laboratory showed significant absolute and relative yearonyear increases in emm1, from 183 (31%) of 587 isolates between March and May 2015, to 267 (42%) of 637 in the same period in 2016 (p<0·0001 vs 2015 values), peaking March 2016 (figure 4A).
To ascertain whether invasive S pyogenes infections might be affected by the emergent M1 UK lineage, we compared the genome sequences of 552 invasive emm1 isolates (appendix p [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] strains obtained in 2015 and 2016 lay within the emergent M1 UK lineage, compared with just five (42%) of 12 obtained between 2013 and 2014 (appendix p 4). Four (13%) of 31 invasive isolates were identical to, or no more than two SNPs different from, noninvasive isolates in the community, consistent with recent transmission. We then analysed the genome sequences of all 552 emm1 sterile site isolates collected between March and May each year from 2013 to 2016, obtained nationally from across different geographical locations in England and Wales. 425 (77%) of 552 invasive emm1 strains were within the new lineage ( figure 4B) , which was present in the UK invasive isolate population as early as 2013. Like M1 global strains, M1 UK strains were phylogenetically distinct from the historical UK emm1 scarlet fever speApositive isolate NCTC8198 and emm1 speCpositive SF370 (appendix p 5). Longitudinal analysis of all available 1240 UK emm1 sequences (appendix p 28) 6-8 obtained from invasive and noninvasive disease cases showed a yearly increase in M1 UK such that, by 2016, M1 UK strains represented more than 80% of all available emm1 isolates in the UK, outnumbering M1 global strains ( figure 5A ).
Phylogenetic comparison of UK emm1 sequences with available international sequences from North America, Nordic regions, UK, and southeast Asia (appendix p 28) [9] [10] [11] confirmed that M1 UK strains were distinct from the globally disseminated pandemic emm1 strains ( figure 5B) . A small number of intermediate isolates (possessing at least 13 of the 27 lineagedefining SNPs, including three SNPs in rofA) were identified in the UK and in Nordic countries, including Denmark (n=16), Finland (n=2), and Sweden (n=4; figure 5b, appendix p 6). 10 M1 UK isolates that possessed all 27 SNPs were, however, unique to the UK, except single sequences isolated in the USA in 2015 9 and in Denmark in 2012, 10 underlining the potential of the new lineage to disseminate internationally ( figure 5B, appendix p 6 ).
Discussion
The modern era of resurgent invasive S pyogenes infections was heralded by reports of virulent strains producing the scarlet fever toxin SpeA 17 and subsequently dominated by the emm1 lineage. 10 In this study, we showed that the originally polyclonal upsurge of scarlet fever in England has more recently been characterised by the emergence of a new emm1 S pyogenes lineage that produces significantly higher levels of SpeA than other contemporary emm1 strains. The new M1 UK lineage showed an apparent fitness advantage within the population, manifest during the scarlet fever seasons of 2015 and 2016. Phylogenetic analysis showed the emergent lineage to be the dominant cause of invasive S pyogenes infections in England in 2016, and indicated that isolates from symptomatic throat infections and scarlet fever represent the major reservoir for invasive infections. The data support the hypothesis that transmission of virulent emm1 strains with enhanced ability to cause scarlet fever could underlie the contem poraneous rise in invasive S pyogenes disease. An unprecedented yearonyear increase in scarlet fever notifications, the underlying basis for which remains unclear, 3, 4 has been seen in England since 2014. Among children aged 1-4 years, the incidence of scarlet fever in 2018 reached 1488 per 100 000. 18 The increase in scarlet fever activity has followed secular changes in factors such as household structure (including use of childcare) and healthcare use, 4 as well as healthcare policies, 19 although causal links have not been established. One unforeseen consequence of medical practice change was that the capacity to investigate such an upsurge was undermined by a reduction in diagnostic testing at the national level. In northwest London, however, where strains are collected for epidemiological analysis, a significant increase in genotype emm4 pharyngitis strains was observed during the 2014 upsurge in scarlet fever, while emm3 was the main genotype associated with physicianreported scarlet fever. 4 emm1 was infrequent in 2014, contrasting with the increase we observed between 2015 and 2016, when genotype emm1 S pyogenes became the dominant cause of upper respiratory tract infections regionally, and invasive disease notifications nationally.
Our genome sequence analysis revealed the emergence of a new emm1 lineage, separated from all other emm1 strains by 27 unique core SNPs, including three within a gene encoding a potential SpeA regulator, RofA. SpeA is usually the only phageencoded superantigen in contemporary emm1 S pyogenes, and has been implicated in the reemergence of severe invasive S pyogenes infections in the 1980s. 10, 17 Although the roles of any specific SNPs were not investigated in the current study, we hypothesise that increased SpeA production by M1 UK strains might be an important contributor to the apparent fitness of the new lineage within the nasopharynx. As a phageencoded superantigen, SpeA is hypothesised to trigger scarlet fever in susceptible children, and has been shown to permit nasopharyngeal infection in humanised models of murine streptococcal infection, plus potential induction of immunity when administered as a toxoid. 20 SpeA can trigger B cell death and abrogate immunoglobulin secretion by the human tonsil, and might contribute to recurrent tonsillitis in children. 21, 22 Thus, production of SpeA might augment the ability of S pyogenes to cause scarlet fever and paediatric pharyngitis. Whether population immunity to SpeA will lead to an eventual decline in the lineage will be of interest to monitor. Griffiths type 1 S pyogenes strains 23 (later designated serotype M1; genotype emm1) were the first to be classically associated with scarlet fever in the early 20th century. Although the oldest emm1 scarlet fever reference strains dating from the 1920s possess and produce phageencoded SpeA 24 , emm1 strains circulating later in the mid20th century lacked phageencoded SpeA. 10 The epidemic success of M1T1 clonal emm1 strains of S pyogenes that subsequently emerged in the 1980s is attributed to acquisition of a more active NADase-streptolysin O locus, as well as acquisition of phageencoded speA2, an allele of speA, and the DNAse encoding gene sda. 10 It is, therefore, surprising that these epidemic emm1 strains, forming the M1 global lineage, apparently produce very little SpeA in vitro. The three SNPs identified in the rofA gene might contribute to the greater abundance of SpeA produced by the emergent M1 UK lineage strains, but appear insufficient alone to account for this change. Gene regulation could be affected by a number of the additional SNPs implicated. A shift to enhanced SpeA expression in the M1 UK lineage might represent just one component of a new phase in the evolution of emm1, although we have not yet explored other aspects of bacterial fitness.
Since the late 2000s, increased scarlet fever notifications have been reported in China, 25 South Korea, 26, 27 and Hong Kong. 28 The M1 UK lineage is distinct from emm1 sequences identified in Asia, where different, non emm1 genotypes have been reported as upsurge associated, and incidence in very young children does not approach that reported in England. 25 Although the acquisitions of novel prophages and antimicrobial resistance have been highlighted as selective pressures in China and Hong Kong, 28 no evidence to suggest that these are factors in England, or that the emergence of a single lineage was a trigger for the original upsurge in England, has been reported. 3 Sampling of the noninvasive reservoir of S pyogenes in our study was limited to a single region of England, and single seasons in 2014-16; thus, we cannot be certain about whether the noninvasive isolate emm genotype or M1 UK proportions altered outside these periods, and the analysis might be skewed through inadvertent inclusion of isolates from outbreaks. The collection used in this study, however, is the only systematic longitudinal collection of noninvasive strains available, and spans 2009-16. None of the samples included was identified as outbreakassociated, although clinical details were imperfect.
Groups of isolates differing by two SNPs or less were identified among noninvasive M1 UK isolates, suggesting recent transmission, whereas no such groups were observed among the M1 global noninvasive isolates, albeit these were from 2009-2014 when emm1 isolates were much less frequently identified. Whether the findings reflect inadvertent sampling of small outbreaks or greater outbreak potential cannot be addressed using these data.
Regardless of the drawbacks of regional sampling, the detection of a new lineage and increase in invasive emm1 infections prompted sequencing of invasive emm1 isolates referred to the national reference laboratory, which confirmed emergence of the same lineage at a national level, and excluded any artefact introduced by regional sampling. Our phylogenetic analysis of invasive isolates focused on the same season, in order to understand a rise in invasive disease, but published genomesequenced invasive strains from the UK outside these months also showed emergence of the same lineage. Although the new lineage outcompeted the contemporary emm1 strains that were sequenced during the period studied, we do not know whether the lineage's success will endure. Genetic analyses were limited by the nature of high throughput shortread sequencing data, which do not provide fully assembled genome sequences for each strain and the phages therein; other lineagespecific differences might yet be identified using different approaches. Our study also did not address the mechanistic basis for fitness in the new lineage or the molecular basis for increased SpeA expression; links to specific SNPs are by association only, and detailed experimental work is underway to address such questions.
Scarlet fever is a visible and readily recognisable manifestation of S pyogenes infection that affects children aged 4-6 years. 3, 4 Importantly, however, the surges observed in scarlet fever are accompanied by seasonal increases in streptococcal sore throat and tonsillitis in the wider population, also predominantly among children. 29 Although we cannot rule out the possibility that the precursors (ie, intermediates) or founders of the M1 UK lineage were imported, we speculate that a generalised increase in S pyogenes activity in the wider population-which coincided with England's scarlet fever upsurges-might have provided the conditions required for adaptation and expansion of emm1 S pyogenes. Whether the M1 UK lineage will be suited to other environments is unknown; management of streptococcal sore throat differs greatly between countries, 30 as do other important factors such as climate. We previously reported the emergence of a new emm89 lineage that had lost the capsule locus but gained an active NADase-streptolysin O locus, in addition to four other major recombination events. 31 This emm89 lineage has now been identified across several continents. 32 The identification of two members of the new M1 UK lineage among isolates outside the UK underlines the potential of such lineages to spread globally. Compared with other genotypes, emm1 S pyogenes has a recognised, heightened association with invasive infections. 9 The expansion of such a lineage within the community reservoir of S pyogenes might be sufficient to explain England's recent increase in invasive infection. Further research to assess the likely effects of M1 UK on infection transmissibility, treatment response, disease burden, and severity is required, coupled with consideration of public health interventions to limit transmission where appropriate. Wider national and global surveillance will provide clearer understanding of the lineage's geographical reach and longerterm fitness, and permit enhanced public health readiness where necessary.
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